Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Characterizing the Role of PLAGL2 in the Establishment of Pre-leukemia and Relapse
EF 2017-18
Résumé
Leukemia is a serious condition which affects approximately 22510 Canadians. Despite advances in research over the last few decades, incidence of new cases and mortality rates show no sign of decline. Recent studies have identified a new population of benign "preleukemic" cells (preLSC) in leukemia, which harbor some, but not all the genetic aberrations present in leukemic cells. These preLSCs have a selection advantage over healthy cells and resist chemotherapy, potentially seeding for both de novo leukemia and relapse.
One of the ongoing projects at the Hope Lab has identified PLAG1 as a potent factor for the expansion of HSPCs ex vivo. However, its overexpression was also observed to exhibit some hallmark preleukemic features such as stem-maintenance and stress-resistance. While PLAG1 transcript is not significantly elevated in clinical datasets of leukemia, its functionally similar family member PLAGL2 is. We hypothesize that the elevation of PLAGL2 commonly observed in leukemia is able to enforce a stress-resistant phenotype within HSPCs to both facilitate the establishment of a preleukemic state and sensitize the cells to future leukemic transformation. I aim to evaluate the stress-resistant, pro-survival, chemoresistant phenotype of HSPCs overexpressing PLAGL2 in both in vitro cultures and murine xenografts. PLAGL2's influence on the transcriptome will also be analyzed to deduce possible effector pathways and establish a potential "preleukemic" signature. Finally, I will screen for drugs known to target key nodes of the effector pathways in hopes of rescuing preleukemic HSPCs and sensitize them to chemotherapeutic treatment.
The establishment of a preleukemic gene signature could be lead to the early identification of at-risk patients and more accurate assessment of prognosis during remission. Meanwhile, the attenuation of the unique pathways identified could also allow for the targeted eradication of preleukemic cells, decreasing the opportunity for relapse.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
387263
Name
Xu Shu Hua
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Characterizing the Role of PLAGL2 in the Establishment of Pre-leukemia and Relapse
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Blood; Chemoresistance; Chemotherapy; Hspc; Leukemia; Plag1; Plagl2; Preleukemia; Stem Cell; Transcriptome
Abstract
Leukemia is a serious condition which affects approximately 22510 Canadians. Despite advances in research over the last few decades, incidence of new cases and mortality rates show no sign of decline. Recent studies have identified a new population of benign "preleukemic" cells (preLSC) in leukemia, which harbor some, but not all the genetic aberrations present in leukemic cells. These preLSCs have a selection advantage over healthy cells and resist chemotherapy, potentially seeding for both de novo leukemia and relapse.
One of the ongoing projects at the Hope Lab has identified PLAG1 as a potent factor for the expansion of HSPCs ex vivo. However, its overexpression was also observed to exhibit some hallmark preleukemic features such as stem-maintenance and stress-resistance. While PLAG1 transcript is not significantly elevated in clinical datasets of leukemia, its functionally similar family member PLAGL2 is. We hypothesize that the elevation of PLAGL2 commonly observed in leukemia is able to enforce a stress-resistant phenotype within HSPCs to both facilitate the establishment of a preleukemic state and sensitize the cells to future leukemic transformation. I aim to evaluate the stress-resistant, pro-survival, chemoresistant phenotype of HSPCs overexpressing PLAGL2 in both in vitro cultures and murine xenografts. PLAGL2's influence on the transcriptome will also be analyzed to deduce possible effector pathways and establish a potential "preleukemic" signature. Finally, I will screen for drugs known to target key nodes of the effector pathways in hopes of rescuing preleukemic HSPCs and sensitize them to chemotherapeutic treatment.
The establishment of a preleukemic gene signature could be lead to the early identification of at-risk patients and more accurate assessment of prognosis during remission. Meanwhile, the attenuation of the unique pathways identified could also allow for the targeted eradication of preleukemic cells, decreasing the opportunity for relapse.
Competitiondate
201710
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Xu, Shu Hua
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~